Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius.

Organon & Co. declined 1.02% in intraday trading, following the news that Genentech, Inc. and Hoffman-La Roche Inc. filed a BPCIA complaint against Shanghai Henlius Biotech, Inc., Shanghai Henlius Biologics Co., Ltd., and Organon LLC and Organon & Co. seeking approval of a pertuzumab biosimilar. Genentech alleges that Organon has commercialization rights in the United States related to the Henlius's pertuzumab and would serve as the U.S. distributor of the biosimilar.